Portal de Periódicos da CAPES

Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease

2023; Multidisciplinary Digital Publishing Institute; Volume: 24; Issue: 7 Linguagem: Inglês

10.3390/ijms24076123

1661-6596

María Del Barrio, Lucía Lavín-Alconero, Álvaro Santos‐Laso, M. Arias, Aitor Odriozola, Juan Carlos Rodriguez‐Duque, Coral Rivas, Paula Iruzubieta, Javier Crespo,

Liver Disease and Transplantation

Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent cause of chronic liver disease (CLD). Currently, the only therapeutic recommendation available is a lifestyle change. However, adherence to this approach is often difficult to guarantee. Alteration of the microbiota and an increase in intestinal permeability seem to be key in the development and progression of NAFLD. Therefore, the manipulation of microbiota seems to provide a promising therapeutic strategy. One way to do so is through faecal microbiota transplantation (FMT). Here, we summarize the key aspects of FMT, detail its current indications and highlight the most recent advances in NAFLD.